We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00970580
First Posted: September 2, 2009
Last Update Posted: September 16, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Biogen
  Purpose
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: BIIB022 With Paclitaxel and Carboplatin Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Biogen:

Primary Outcome Measures:
  • To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin [ Time Frame: 6 months ]

Enrollment: 18
Study Start Date: October 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIIB022 in Combination with Paclitaxel and Carboplatin
BIIB022 in Combination with Paclitaxel and Carboplatin
Drug: BIIB022 With Paclitaxel and Carboplatin
Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
Other Names:
  • Taxol
  • Paraplatin
  • BIIB022
  • Taxane
  • Anti-IGF-1R
  • Cytotoxic
  • Mitotic Inhibitor
  • IGF-1R
  • Alkylating agent

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >/= 18 years old
  • Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
  • ECOG Performance Status 0 or 1

Exclusion Criteria:

  • History of another primary cancer within 3 years
  • Any prior or concurrent investigational or standard therapy for treatment of NSCLC
  • Prior anti-IGF-1R therapy
  • Unstable diabetes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00970580


Locations
United States, California
Resesarch Site
Los Angeles, California, United States
Resesarch Site
San Diego, California, United States
United States, Colorado
Resesarch Site
Denver, Colorado, United States
Sponsors and Collaborators
Biogen
  More Information

Responsible Party: Therese Senta-McMillian, Clinical Team Manager, PRA International
ClinicalTrials.gov Identifier: NCT00970580     History of Changes
Other Study ID Numbers: 212-LC-101
First Submitted: September 1, 2009
First Posted: September 2, 2009
Last Update Posted: September 16, 2013
Last Verified: November 2011

Keywords provided by Biogen:
BIIB022
Stage IV
Taxol
Stage IIIB
Carboplatin
Paclitaxel
Non Small Cell Lung Cancer
Treatment Naive
Anti IGF1R
NSCLC
Open Label
IGF1R
Paraplatin
Cytotoxic
Mitotic Inhibitor
Taxane
Alkylating agent

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Paclitaxel
Antimitotic Agents
Taxane
Albumin-Bound Paclitaxel
Carboplatin
Mecasermin
Alkylating Agents
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs
Immunologic Factors